Document Detail


Royal Jelly Acid, 10-Hydroxy-trans-2-Decenoic Acid, as a Modulator of the Innate Immune Responses.
MedLine Citation:
PMID:  23061418     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
Royal jelly is a food for queen and larvae honeybees. 10-Hydroxy-trans-2-decenoic acid (10H2DA; "royal jelly acid") is the principal lipid component in royal jelly. Several pharmacological activities of 10H2DA have been reported: anti-tumor, anti-biotic, immunomodulatory, estrogenic and neurogenic. We recently revealed an inhibitory effect of 10H2DA in innate immune signals. Despite appreciable advances in studies on innate immune signals after the identification of Toll-like receptors as innate immune receptors, few studies have reported the effect of 10H2DA on innate immune signals. In this review, we focus on recent advances in the evaluation of the biological activities of 10H2DA (especially immunomodulatory activities). We also discuss the molecular mechanisms underpinning these biological activities, which could lead to new therapeutic targets for the treatment of immune disorders.
Authors:
Tsuyoshi Sugiyama; Keita Takahashi; Hiroshi Mori
Related Documents :
23338678 - The pro-inflammatory cytokine tnf-α regulates the activity and expression of the serot...
24710278 - Stat1β is not dominant negative and is capable of contributing to ifnγ-dependent inna...
24610528 - Neuroprotective and anti-apoptotic propensity of bacopa monniera extract against sodium...
23007808 - Effect of tonsillar mononuclear cell supernatants in patients with iga nephropathy on r...
11710518 - Exogenous nitric oxide inhibits experimental autoimmune uveoretinitis development in le...
22287708 - The ikkα-dependent nf-κb p52/relb noncanonical pathway is essential to sustain a cxcl...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2012-10-09
Journal Detail:
Title:  Endocrine, metabolic & immune disorders drug targets     Volume:  -     ISSN:  2212-3873     ISO Abbreviation:  Endocr Metab Immune Disord Drug Targets     Publication Date:  2012 Oct 
Date Detail:
Created Date:  2012-10-15     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101269157     Medline TA:  Endocr Metab Immune Disord Drug Targets     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Affiliation:
Department of Biopharmaceutical Sciences, Laboratory of Microbiology, Gifu Pharmaceutical University, 1-25-4 Daigaku-Nishi, Gifu 501-1196, Japan. sugiyama@gifu-pu.ac.jp.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Cystoid Macular Edema Without Leakage Secondary to Nab-Paclitaxel (Abraxane): Clinical Experience wi...
Next Document:  Molecular basis for nanoscopic membrane curvature generation from quantum mechanical models and synt...